Aptarion Biotech
Germany - BerlinBiotechnology
Focus: Aptarion Biotech is a German biotechnology company specializing in L-aptamers, a novel therapeutic modality targeting infectious diseases. The company is in early clinical development with a focused pipeline in community-acquired pneumonia.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Aptarion Biotech
AI assessmentNot HiringNo open roles listed right now. Follow Aptarion Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AON-D21
Community-acquired PneumoniaClinical Trials (3)
NCT05962606Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Phase 2Help build intelligence for Aptarion Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.